Resources
Quick Reference
Beta-lactam and aminoglyoside user guide
Videos
Vancomycin (intermittend infusion)
Piperacillin (extended infusion)
Piperacillin (continuous infusion)
Original articles
S.G. Wicha, M.G. Kees, A. Solms, I.K. Minichmayr, A. Kratzer, C. Kloft
TDMx – a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine.
Int. J. Antimicrob. Agents. 45: 442-444 (2015).
doi: 10.1016/j.ijantimicag.2014.12.010
M.A. Barras, D. Serisier, S. Hennig, K. Jess, R.L.G. Norris
Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis
Antimicrob. Agents Chemother. 60: 6698-6702 (2016).
doi: 10.1128/AAC.01131-16
A. Broeker, M. Nardecchia, K.P. Klinker, H. Derendorf, R.O. Day, D.J. Marriott, J.E. Carland, S.L. Stocker, S.G. Wicha
Towards precision dosing of vancomycin: A systematic evaluation of pharmacometric models for Bayesian forecasting.
Clin. Microbiol. Infect. 25: 1286e1-e7 (2019).
doi: 10.1016/j.cmi.2019.02.029
C.B. Cunio, D.W. Uster, J.E. Carland, H. Buscher, Z. Liu, J. Brett, M. Stefani, G.R.D. Jones, R.O. Day, S..G. Wicha, S.L. Stocker
Towards precision dosing of vancomycin in critically ill patients: A evaluation of the predictive performanceof pharmacometric models in ICU patients.
Clin. Microbiol. Infect. (ahead of print) (2020).
doi: 10.1016/j.cmi.2020.07.005
D.W. Uster, S.L. Stocker, J.E. Carland, J. Brett, D.J. E. Marriott, R.O. Day, S.G. Wicha
A Model Averaging/Selection Approach Improves the Predictive Performance of Model-Informed Precision Dosing: Vancomycin as a Case Study.
Clin. Pharmacol. Ther. 109: 175-183 (2021).
doi: 10.1002/cpt.2065
S.G. Wicha, A.G. Märtson, E.I. Nielsen, B.C.P. Koch, L.E. Friberg, J.W. Alffenaar, I.K. Minichmayr
From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics.
Clin. Pharmacol. Ther. 109: 928-941 (2021).
doi: 10.1002/cpt.2202
D.W. Uster, S.G. Wicha
Optimized sampling to estimate vancomycin drug exposure: comparison of pharmacometric and equation-based approaches in a simulation-estimation study.
CPT: Pharmacometrics & Systems Pharmacol- 11: 711-720 (2022).
doi: 10.1002/psp4.12782
D.W. Uster, P. Chowdary, A. Riddell, C. Garcia, E. Aradom, M. Musarara, S.G. Wicha
Dosing for Personalized Prophylaxis in Hemophilia A highly varies on the underlying Population Pharmacokinetic Models.
Ther. Drug. Monit. 44: 665-673 (2022).
doi: 10.1097/FTD.0000000000000983
W. Kantasiripitak, Outtier A., S.G. Wicha, A. Kensert, Z. Wang, J. Sabino, S. Vermeire, D. Thomas, M. Ferrante, E. Dreesen
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.
CPT: Pharmacometrics & Systems Pharmacol- 11: 1045-1059 (2022).
doi: 10.1002/psp4.12813
W. Kantasiripitak, S.G. Wicha, D. Thomas, I. Hoffman, M. Ferrante, S. Vermeire, K. van Hoeve, E. Dreesen
A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
J. Chrohns Colitis. (2023).
doi: 10.1093/ecco-jcc/jjad009
Denise Kohkemper and David Uster (University of Hamburg) are acknowledged for their assistance in creating the tutorial videos.